floatz | AI-Driven Scientific Due Diligence for Life-Science Investors

What

floatz is an AI-driven scientific due diligence product for life-science investors. It is designed to assess the scientific strength behind investment opportunities by turning fragmented evidence into decision-grade risk intelligence.

The product appears positioned as a specialized diligence layer for biotech and broader life-science investing. Its core workflow combines a scientific knowledge graph, machine learning risk detection, and agentic AI with human review to evaluate claims in context and surface weak, negative, or non-obvious scientific risks.

Features

• Interconnected scientific knowledge graph: Represents science, clinical trials, intellectual property, and people in one evidence system so claims can be assessed in relation to the broader body of evidence.
• Contextual claim evaluation: Moves beyond isolated claim review by analyzing how each scientific assertion fits within surrounding evidence and dependencies.
• Machine learning risk signals: Uses ML models to infer weak, negative, and harder-to-detect risks across fragmented and noisy datasets.
• Agentic AI analysis: AI agents convert inferred signals into structured conclusions, helping users move from raw evidence to investment-oriented interpretation.
• Human-reviewed outputs: Adds human review to improve clarity and accountability in the final diligence conclusions.
• Decision-grade diligence focus: Frames outputs for defensible investment decision-making rather than only scientific literature review.

Helpful Tips

• Check evidence coverage carefully: For any scientific diligence platform, verify which evidence domains are actually included and how current they are, since decision quality depends heavily on source completeness.
• Validate explainability requirements: Investors should confirm how inferred risk signals are traced back to evidence, especially when conclusions may affect investment committees or partner discussions.
• Use it as part of a broader diligence process: Scientific risk intelligence is valuable, but it should likely be combined with market, regulatory, commercial, and management diligence unless the provider explicitly covers those areas.
• Review human-in-the-loop design: When evaluating products in this category, assess who reviews outputs, how disagreements are handled, and where accountability sits in the final recommendation.
• Prioritize workflow fit: Adoption is easier when outputs match existing memo, IC, and portfolio review processes rather than requiring teams to invent a new diligence format.

OpenClaw Skills

Within the OpenClaw ecosystem, floatz could likely support specialized skills for biotech investment research, scientific claim validation, and evidence-based memo drafting. A practical agent workflow might gather target-company claims, map them against scientific and trial evidence, summarize inferred risk signals, and produce structured diligence notes for analysts or investment teams. The source page does not state a native OpenClaw integration, so this should be treated as a likely use case rather than a confirmed capability.

More advanced OpenClaw agents could be built around portfolio monitoring, thesis stress-testing, or partner-meeting preparation for life-science funds. In a broader industry sense, combining floatz-style scientific risk intelligence with OpenClaw orchestration could help investors standardize how they examine scientific uncertainty, make assumptions more explicit, and reduce reliance on ad hoc expert review alone.